BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30

• Drug Development

  Ipsen Release: Endocrine Practice Publishes ELECT Phase III Trial Results In Adults With Carcinoid Syndrome

  June 6, 2016

   · 

  10 min read
• Drug Development

  ASCO2016: Ariad’s Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study

  June 6, 2016

   · 

  10 min read
• Drug Development

  ASCO2016: Kite Pharma Announces The First Meta-Analysis Of Outcomes In Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)

  June 6, 2016

   · 

  5 min read
• Drug Development

  New Study Led By John Theurer Cancer Center Researcher Demonstrates Potential Therapeutic Benefit Of TPI 287 With Bevacizumab In Treatment Of Aggressive Brain Cancer

  June 6, 2016

   · 

  3 min read
• Pharm Country

  NYU Langone Medical Center Release: Study Shows Why Immune-Boosting Therapy Doesn’t Work For Everyone With Widespread Melanoma

  June 6, 2016

   · 

  4 min read
• Drug Development

  ASCO2016: Kite Pharma Presents Ongoing Complete Responses At 9 Months In Phase I Of ZUMA-1 In Patients With Chemorefractory Non-Hodgkin Lymphoma

  June 6, 2016

   · 

  5 min read
• Drug Development

  Novartis AG Pivotal Data For Tafinlar + Mekinist Demonstrated A 63 Percent Overall Response Rate In Treating Rare Form Of Lung Cancer

  June 6, 2016

   · 

  19 min read
• Drug Development

  ASCO2016 : AbbVie Presents Encouraging Phase 1 Data For Investigational Medicine ABT-414 As Monotherapy In Patients With An Aggressive Brain Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting

  June 6, 2016

   · 

  8 min read
• Pharm Country

  ASCO2016: Novartis Pharmaceuticals Corporation Data Show More Than 50 Percent Of Eligible Ph+ CML Patients Maintain Treatment-Free Remission (TFR) After Stopping Tasigna

  June 6, 2016

   · 

  18 min read
• Drug Development

  ASCO2016: OBI Pharma Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting

  June 6, 2016

   · 

  4 min read